347 related articles for article (PubMed ID: 23579273)
1. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.
Kocak H; Ackermann S; Hero B; Kahlert Y; Oberthuer A; Juraeva D; Roels F; Theissen J; Westermann F; Deubzer H; Ehemann V; Brors B; Odenthal M; Berthold F; Fischer M
Cell Death Dis; 2013 Apr; 4(4):e586. PubMed ID: 23579273
[TBL] [Abstract][Full Text] [Related]
2. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
3. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
4. Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.
Young SA; McCabe KE; Bartakova A; Delaney J; Pizzo DP; Newbury RO; Varner JA; Schlaepfer DD; Stupack DG
PLoS One; 2015; 10(5):e0120815. PubMed ID: 25973900
[TBL] [Abstract][Full Text] [Related]
5. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
[TBL] [Abstract][Full Text] [Related]
6. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
7. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
8. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.
Guglielmi L; Cinnella C; Nardella M; Maresca G; Valentini A; Mercanti D; Felsani A; D'Agnano I
Cell Death Dis; 2014 Feb; 5(2):e1081. PubMed ID: 24556696
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
10. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.
Berwanger B; Hartmann O; Bergmann E; Bernard S; Nielsen D; Krause M; Kartal A; Flynn D; Wiedemeyer R; Schwab M; Schäfer H; Christiansen H; Eilers M
Cancer Cell; 2002 Nov; 2(5):377-86. PubMed ID: 12450793
[TBL] [Abstract][Full Text] [Related]
11. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
13. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.
Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X
Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736
[TBL] [Abstract][Full Text] [Related]
14. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression.
Kitanaka C; Kato K; Ijiri R; Sakurada K; Tomiyama A; Noguchi K; Nagashima Y; Nakagawara A; Momoi T; Toyoda Y; Kigasawa H; Nishi T; Shirouzu M; Yokoyama S; Tanaka Y; Kuchino Y
J Natl Cancer Inst; 2002 Mar; 94(5):358-68. PubMed ID: 11880474
[TBL] [Abstract][Full Text] [Related]
15. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
16. Expression profiling of favorable and unfavorable neuroblastomas.
Hiyama E; Hiyama K; Yamaoka H; Sueda T; Reynolds CP; Yokoyama T
Pediatr Surg Int; 2004 Jan; 20(1):33-8. PubMed ID: 14691637
[TBL] [Abstract][Full Text] [Related]
17. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
18. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.
Ikram F; Ackermann S; Kahlert Y; Volland R; Roels F; Engesser A; Hertwig F; Kocak H; Hero B; Dreidax D; Henrich KO; Berthold F; Nürnberg P; Westermann F; Fischer M
Mol Oncol; 2016 Feb; 10(2):344-59. PubMed ID: 26598443
[TBL] [Abstract][Full Text] [Related]
19. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
20. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
